Beneficial effect of oral tigecycline treatment on clostridium difficile infection in gnotobiotic piglets

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7560-7564

  Kim, Hyeun Bum ^a,b   Zhang, Quanshun ^a   Sun, Xingmin ^a   Beamer, Gillian ^a   Wang, Yuankai ^a   Tziporia, Saul ^a  

^a TUFTS UNIVERSITY   (United States)

^b Dankook University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; RNA 16S; TIGECYCLINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; ANTIINFECTIVE AGENT; MBX-500; MINOCYCLINE; PYRIMIDINONE DERIVATIVE; QUINOLONE DERIVATIVE; VANCOMYCIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DYSPNEA; EXPERIMENTAL PIG; FECES CULTURE; GNOTOBIOTICS; HOMEOSTASIS; HUMAN; IN VITRO STUDY; INTESTINE FLORA; LETHARGY; MICROBIAL COMMUNITY; MICROSCOPY; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; RECURRENCE RISK; SALVAGE THERAPY; WEAKNESS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG ADMINISTRATION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GERMFREE ANIMAL; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; MICROFLORA; ORAL DRUG ADMINISTRATION; PATHOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PIG; SECRETION (PROCESS);

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG ADMINISTRATION SCHEDULE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; GERM-FREE LIFE; HUMANS; INTERLEUKIN-8; MICROBIOTA; MINOCYCLINE; PYRIMIDINONES; SWINE; VANCOMYCIN;

EID: 84913570623     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03447-14     Document Type: Article

References (25)

1. Kachrimanidou M, Malisiovas N. 2011. Clostridium difficile infection: a comprehensive review. Crit. Rev. Microbiol. 37:178-187. http://dx.doi .org/10.3109/1040841X.2011.556598.
2. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C, and Fecal Microbiota Transplantation Workgroup. 2011. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin. Gastroenterol. Hepatol. 9:1044-1049. http://dx.doi.org/10.1016/j .cgh.2011.08.014.
3. Wilcox MH. 2007. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin. Microbiol. Infect. 13:949-952. http://dx .doi.org/10.1111/j.1469-0691.2007.01792.x.
4. Jump RL, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. 2011. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob. Agents Chemother. 55:546-549. http://dx.doi.org/10.1128/AAC.00839-10.
5. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, Welte T, Kuijper EJ. 2009. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48:1732-1735. http://dx.doi .org/10.1086/599224.
6. Steele J, Feng H, Parry N, Tzipori S. 2010. Piglet models of acute or chronic Clostridium difficile illness. J. Infect. Dis. 201:428-434. http://dx .doi.org/10.1086/649799.
7. Steele J, Zhang Q, Beamer G, Butler M, Bowlin T, Tzipori S. 2013. MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets. Antimicrob. Agents Chemother. 57:4039-4041. http: //dx.doi.org/10.1128/AAC.00304-13.
8. Wang H, Sun X, Zhang Y, Li S, Chen K, Shi L, Nie W, Kumar R, Tzipori S, Wang J, Savidge T, Feng H. 2012. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect. Immun. 80:2678-2688. http://dx.doi.org/10.1128/IAI.00215-12.
9. Canny G, Drudy D, Macmathuna P, O'farrelly C, Baird AW. 2006. Toxigenic C. difficile induced inflammatory marker expression by human intestinal epithelial cells is asymmetrical. Life Sci. 78:920-925. http://dx .doi.org/10.1016/j.lfs.2005.05.102.
10. Jiang ZD, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M. 2006. A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am. J. Gastroenterol. 101:1112-1116. http://dx.doi.org/10.1111/j.1572-0241 .2006.00482.x.
11. Meyer GK, Neetz A, Brandes G, Tsikas D, Butterfield JH, Just I, Gerhard R. 2007. Clostridium difficile toxins A and B directly stimulate human mast cells. Infect. Immun. 75:3868-3876. http://dx.doi.org/10 .1128/IAI.00195-07.
12. Pastoret P, Griebel P, Bazin H, Govaerts A (ed). 1998. Handbook of vertebrate immunology. Academic Press, San Diego, CA.
13. Berg RD. 1996. The indigenous gastrointestinal microflora. Trends Microbiol. 4:430-435.
14. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. 2005. Host-bacterial mutualism in the human intestine. Science 307:1915-1920. http://dx.doi.org/10.1126/science.1104816.
15. Owens RC, Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 46 (Suppl 1) :S19-S31. http://dx.doi.org/10.1086 /521859.
16. Zhang Q, Widmer G, Tzipori S. 2013. A pig model of the human gastrointestinal tract. Gut Microbes 4:193-200. http://dx.doi.org/10.4161/gmic.23867.
17. Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, Kulam-Syed-Mohideen AS, McGarrell DM, Marsh T, Garrity GM, Tiedje JM. 2009. The Ribosomal Database Project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 37:D141-D145. http://dx.doi.org/10 .1093/nar/gkn879.
18. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Pena AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7:335-336. http://dx.doi.org/10.1038/nmeth.f.303.
19. Kim HB, Borewicz K, White BA, Singer RS, Sreevatsan S, Tu ZJ, Isaacson RE. 2011. Longitudinal investigation of the age-related bacterial diversity in the feces of commercial pigs. Vet. Microbiol. 153:124-133. http://dx.doi.org/10.1016/j.vetmic.2011.05.021.
20. Kim HB, Borewicz K, White BA, Singer RS, Sreevatsan S, Tu ZJ, Isaacson RE. 2012. Microbial shifts in the swine distal gut in response to the treatment with antimicrobial growth promoter, tylosin. Proc. Natl. Acad. Sci. U. S. A. 109:15485-15490. http://dx.doi.org/10.1073/pnas.1205147109.
21. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, Gordon JI. 2009. The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci. Transl. Med. 1:6ra14. http: //dx.doi.org/10.1126/scitranslmed.3000322.
22. Lode H, Von der Hoh N, Ziege S, Borner K, Nord CE. 2001. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand. J. Infect. Dis. 33:899-903. http://dx.doi.org/10 .1080/00365540110076714.
23. De La Cochetière MF, Durand T, Lepage P, Bourreille A, Galmiche JP, Doré J. 2005. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. J. Clin. Microbiol. 43:5588-5592. http: //dx.doi.org/10.1128/JCM.43.11.5588-5592.2005.
24. Baines SD, Saxton K, Freeman J, Wilcox MH. 2006. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J. Antimicrob. Chemother. 58: 1062-1065. http://dx.doi.org/10.1093/jac/dkl364.
25. Bassis CM, Theriot CM, Young VB. 2014. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob. Agents Chemother. 58: 2767-2774. http://dx.doi.org/10.1128/AAC.02262-13.